Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis.

Gurion, Ronit; Gafter-Gvili, Anat; Vidal, Liat; Leader, Avi; Ram, Ron; Shacham-Abulafia, Adi; Paul, Mical; Ben-Bassat, Isaac; Shpilberg, Ofer; Raanani, Pia

Gurion, Ronit; Gafter-Gvili, Anat; Vidal, Liat; Leader, Avi; Ram, Ron; Shacham-Abulafia, Adi; Paul, Mical; Ben-Bassat, Isaac; Shpilberg, Ofer; Raanani, Pia.

Affiliation

Gurion R; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Tel Aviv University, Israel. shay_gr@hotmail.com

Haematologica ; 98(1): 95-102, 2013 Jan.

Article in En | MEDLINE | ID: mdl-22875617

Subject(s)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors/therapeutic use; Protein-Tyrosine Kinases/antagonists & inhibitors; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality; Protein Kinase Inhibitors/pharmacology; Protein-Tyrosine Kinases/metabolism; Randomized Controlled Trials as Topic/methods; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein-Tyrosine Kinases / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Protein Kinase Inhibitors Type of study: Clinical_trials / Etiology_studies / Systematic_reviews Limits: Humans Language: En Journal: Haematologica Year: 2013 Type: Article Affiliation country: Israel

Fulltext

XML

PubMed Links

Search on Google